Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhejiang Hisun Pharmaceutical Co's Days Payable or its related term are showing as below:
SHSE:600267'
s Days Payable Range Over the Past 10 Years
Min: 56.6 Med: 80.63 Max: 88.33
Current: 72.46
During the past 13 years, Zhejiang Hisun Pharmaceutical Co's highest Days Payable was 88.33. The lowest was 56.60. And the median was 80.63.
SHSE:600267's Days Payable is ranked worse than 59.83% of 926
companies
in the Drug Manufacturers industry
Industry Median: 90.22
vs SHSE:600267: 72.46
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Hisun Pharmaceutical Co Days Payable Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Hisun Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Hisun Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Hisun Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Zhejiang Hisun Pharmaceutical Co's Days Payable falls into.
Zhejiang Hisun Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) has a Days Payable of 76.81 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. This is near median its historical median of 80.63. Over the past decade, Zhejiang Hisun Pharmaceutical Co's Days Payable has ranged from 56.60 to 88.33. According to the industry distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #554 out of 926 companies in the Drug Manufacturers industry, placing it in the top 59.8%.
Is Zhejiang Hisun Pharmaceutical Co's Days Payable too high?
Zhejiang Hisun Pharmaceutical Co's current Days Payable of 76.81 is near median its 10-year median of 80.63. Over the past 10 years, this metric has ranged from a low of 56.60 to a high of 88.33. The Drug Manufacturers industry median Days Payable is 90.22. Zhejiang Hisun Pharmaceutical Co's value of 76.81 is 14.9% below this industry median. Based on the distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #554 out of 926 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zhejiang Hisun Pharmaceutical Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Hisun Pharmaceutical Co's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #554 out of 926 companies for Days Payable. This places Zhejiang Hisun Pharmaceutical Co in the lower half of its industry. The industry median Days Payable is 90.22. Zhejiang Hisun Pharmaceutical Co's value of 76.81 is 14.9% below this benchmark. Historically, Zhejiang Hisun Pharmaceutical Co's own Days Payable has ranged from 56.60 to 88.33 over the past decade. While the company's 10-year median is 80.63 vs. the industry median of 90.22, Zhejiang Hisun Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Hisun Pharmaceutical Co's current Days Payable of 76.81 is 14.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Hisun Pharmaceutical Co's current Days Payable is 76.81, which is near median its own 10-year median of 80.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Hisun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co (SHSE:600267) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.86, compared to a current price of ¥11.80 — trading 33.2% above its estimated fair value. The current Days Payable is 76.81, which is near median its 10-year median of 80.63 and 14.9% below the Drug Manufacturers industry median of 90.22. Zhejiang Hisun Pharmaceutical Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zhejiang Hisun Pharmaceutical Co (SHSE:600267), the current Days Payable is 76.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥11.80 is trading 33.2% above its estimated GF Value™ of ¥8.86.
GuruFocus considers Zhejiang Hisun Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:600267:
Days Payable: 76.81 (near median its 10-year median of 80.63)
GF Value™: ¥8.86 vs. price of ¥11.80 (33.2% above fair value)
Industry Position: 14.9% below the Drug Manufacturers median (#554 of 926)
No single metric tells the full story. See the SHSE:600267 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Hisun Pharmaceutical Co Business Description
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
58GF Score
Get the complete analysis for SHSE:600267
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600267 has been successfully added to your 
